FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Why it matters
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Article tone
Neutral
How the article is written, as reported by the source.
Expected market reaction
Evidence trail
Evidence
Source
CNBC
Claim
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
AI inference
Neutral · 94%
Generated
2026-03-18 17:17
AI provenance
Technical identifiers
- Provider tag
- huggingface-ProsusAI/finbert
- Analysis version
- huggingface-ProsusAI/finbert
- Article id
- 59701
Original source
Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.
Original article published by CNBC on March 18, 2026. Analysis and insights provided by AnalystMarkets AI.